Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy

Sara Keller, Deborah Williams, Mitra Gavgani, David Hirsch, John Adamovich, Dawn Hohl, Ayse Gurses, Sara Cosgrove

Research output: Contribution to journalArticle

Abstract

To better monitor patients on outpatient parenteral antimicrobial therapy (OPAT), we need an improved understanding of risk factors for and timing of OPAT-associated adverse drug events (ADEs). Methods. We analyzed a prospective cohort of patients on OPAT discharged from 2 academic medical centers. Patients underwent chart abstraction and a telephone survey. Multivariable analyses estimated adjusted incident rate ratios (aIRR) between clinical and demographic risk factors and clinician-determined clinically significant ADEs. Descriptive data were used to present patient-reported ADEs. Results. Of 339 patients enrolled in the study, 18.0% experienced an ADE (N = 65), of which 49 were significant (14.5%, 2.24/1000 home-OPAT days). Patients with longer courses of therapy had lower rates of ADEs compared with patients treated for 0-13 days (14-27 days: AIRR, 0.44; 95% confidence interval [CI], 0.20-0.99; at least 28 days: AIRR, 0.11; 95% CI, 0.056-0.21). Risk factors for ADEs included female gender and receipt of daptomycin or vancomycin, while treatment for uncomplicated bacteremia and empiric treatment were associated with lower rates of ADEs. Conclusions. OPAT-related ADEs were common and often occurred within 2 weeks of hospital discharge. Patients on OPAT should be monitored more closely for ADEs, including clinical assessment and laboratory monitoring, especially within the first weeks after hospital discharge and particularly among women and patients who receive vancomycin.

Original languageEnglish (US)
Pages (from-to)11-19
Number of pages9
JournalClinical Infectious Diseases
Volume66
Issue number1
DOIs
StatePublished - Jan 1 2018

    Fingerprint

Keywords

  • adverse drug events
  • antibiotic side effect
  • drug monitoring
  • OPAT
  • vancomycin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this